Giant Biogene Holding Balance Sheet Health
Financial Health criteria checks 6/6
Giant Biogene Holding has a total shareholder equity of CN¥6.0B and total debt of CN¥0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are CN¥7.8B and CN¥1.8B respectively. Giant Biogene Holding's EBIT is CN¥2.0B making its interest coverage ratio -31.7. It has cash and short-term investments of CN¥6.1B.
Key information
0%
Debt to equity ratio
CN¥0
Debt
| Interest coverage ratio | -31.7x |
| Cash | CN¥6.06b |
| Equity | CN¥5.97b |
| Total liabilities | CN¥1.81b |
| Total assets | CN¥7.78b |
Recent financial health updates
No updates
Recent updates
Giant Biogene Holding Co., Ltd. (HKG:2367) Shares Could Be 50% Below Their Intrinsic Value Estimate
Nov 20
Revenue Beat: Giant Biogene Holding Co., Ltd. Beat Analyst Estimates By 12%
Aug 21Does Giant Biogene Holding (HKG:2367) Deserve A Spot On Your Watchlist?
Aug 09Giant Biogene Holding Co., Ltd.'s (HKG:2367) Popularity With Investors Is Clear
Jul 01Is Giant Biogene Holding Co., Ltd. (HKG:2367) Trading At A 32% Discount?
Apr 17Investors Interested In Giant Biogene Holding Co., Ltd.'s (HKG:2367) Earnings
Mar 28Giant Biogene Holding Co., Ltd. Just Recorded A 6.9% EPS Beat: Here's What Analysts Are Forecasting Next
Mar 27Do Giant Biogene Holding's (HKG:2367) Earnings Warrant Your Attention?
Dec 24Financial Position Analysis
Short Term Liabilities: 2367's short term assets (CN¥6.7B) exceed its short term liabilities (CN¥1.8B).
Long Term Liabilities: 2367's short term assets (CN¥6.7B) exceed its long term liabilities (CN¥50.1M).
Debt to Equity History and Analysis
Debt Level: 2367 is debt free.
Reducing Debt: 2367 has not had any debt for past 5 years.
Debt Coverage: 2367 has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: 2367 has no debt, therefore coverage of interest payments is not a concern.
Balance Sheet
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/18 03:55 |
| End of Day Share Price | 2024/12/18 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Giant Biogene Holding Co., Ltd. is covered by 28 analysts. 21 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Junhao Fan | China International Capital Corporation Limited |
| Zhuonan Xu | China International Capital Corporation Limited |
| Joseph Wong | China Merchants Securities (HK) Co., Ltd |